MetabolicPreliminary grade

Retatrutide

A triple GIP/GLP-1/glucagon agonist showing >20% weight loss in phase 2 — the most powerful incretin in the pipeline.

Verdict — C · Emerging / Mixed

Unprecedented phase-2 weight-loss signal and strong phase-3 enrollment, but no approval, limited independent sourcing, and an expected GLP-1-class safety profile with additional glucagon-axis unknowns. Watch the TRIUMPH readout; buy nothing from the gray market.

PepScore / 100

CEmerging / Mixed

How we compute this →

Overview

Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist (Eli Lilly) currently in phase-3 TRIUMPH trials with no regulatory approval yet. Phase-2 data demonstrated up to 24% body-weight reduction — the largest in any published incretin trial. Gray-market supply exists but is unverified; the compound is not yet commercially manufactured for consumer use.

PepScore Breakdown — the four axes

Evidence

35% weight

80/100

How strong is the published human science?

Human data depth30/40

Regulatory & registry status26/30

Reproducibility & consistency15/20

Mechanism characterized in humans9/10

Sourcing & COA

30% weightOur moat

42/100

Can a buyer obtain an independently-verified, high-purity version? — our proprietary layer.

Independent 3rd-party testing15/35

Verified purity %13/30

COA transparency & batch traceability8/20

Multi-vendor verified availability6/15

Safety & Risk

25% weight

48/100

What is the real-world harm potential?

Documented AEs / toxicity18/40

Contraindication breadth12/25

Regulatory warnings9/20

Therapeutic index / margin9/15

Practicality

10% weight

52/100

How easy is it to actually run a verified version?

Verified-source availability15/35

Cost / value per cycle12/25

Reconstitution & administration16/25

Storage & stability9/15

Sources & Citations

Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.

Want a clinical path?

Talk to a licensed provider about Retatrutide and whether it's appropriate for your situation.

Talk to a Provider ↗

Telehealth. Not medical advice — for educational purposes.

PepScore58/100 · C

Last gradedJune 28, 2026

Next re-grade triggerFDA approval of retatrutide would dramatically lift Evidence, Registry, and Practicality axes.

Price Index Vendor Grades Providers COA Lookup All Rankings

Get the PepEvolution Dispatch

Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.

Free. Unsubscribe anytime. Research/educational content only.

Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.